129 related articles for article (PubMed ID: 36509070)
21. Impact of multidisciplinary tumor board discussion on palliation of patients with esophageal or gastro-esophageal junction cancer: a population-based study.
Vermeulen BD; Bruggeman L; Bac DJ; Schrauwen RWM; Epping LSM; Scheffer RCH; Tan ACITL; Groenen MJM; Verhoeven RHA; Siersema PD
Acta Oncol; 2020 Apr; 59(4):410-416. PubMed ID: 32067535
[No Abstract] [Full Text] [Related]
22. Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials.
Thientosapol ES; Tran TT; Della-Fiorentina SA; Adams DH; Chantrill L; Stockler MR; Kiely BE
Intern Med J; 2013 Aug; 43(8):883-8. PubMed ID: 23656187
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Moehler M; Mahlberg R; Heinemann V; Obermannová R; Kubala E; Melichar B; Weinmann A; Scigalla P; Tesařová M; Janda P; Hédouin-Biville F; Mansoor W
Gastric Cancer; 2017 Mar; 20(2):358-367. PubMed ID: 27255289
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of survival and prognosis of Siewert Ⅱ/Ⅲ esophagogastric junction adenocarcinoma patients with non-operative acute upper gastrointestinal hemorrhage].
Tian L; Yu L
Zhonghua Yi Xue Za Zhi; 2020 Jun; 100(24):1881-1885. PubMed ID: 32575932
[No Abstract] [Full Text] [Related]
25. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
van der Kaaij RT; Koemans WJ; van Putten M; Snaebjornsson P; Luijten JCHBM; van Dieren JM; Cats A; Lemmens VEPP; Verhoeven RHA; van Sandick JW
Eur J Cancer; 2020 May; 130():23-31. PubMed ID: 32171106
[TBL] [Abstract][Full Text] [Related]
26. Long-term trends and survival analysis of esophageal and gastric cancer in Yangzhong, 1991-2013.
Hua Z; Zheng X; Xue H; Wang J; Yao J
PLoS One; 2017; 12(3):e0173896. PubMed ID: 28288195
[TBL] [Abstract][Full Text] [Related]
27. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.
Blank S; Stange A; Sisic L; Roth W; Grenacher L; Sterzing F; Burian M; Jäger D; Büchler M; Ott K
Langenbecks Arch Surg; 2013 Feb; 398(2):211-20. PubMed ID: 23224565
[TBL] [Abstract][Full Text] [Related]
28. A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands.
Pape M; Vissers PAJ; Kato K; Haj Mohammad N; Klarenbeek B; van Laarhoven HWM; Matsuda T; Verhoeven RHA
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13323-13330. PubMed ID: 37486395
[TBL] [Abstract][Full Text] [Related]
29. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis.
Dubecz A; Gall I; Solymosi N; Schweigert M; Peters JH; Feith M; Stein HJ
J Thorac Oncol; 2012 Feb; 7(2):443-7. PubMed ID: 22173700
[TBL] [Abstract][Full Text] [Related]
30. Improvement in survival for patients with synchronous metastatic esophageal cancer in the south of the Netherlands from 1994 to 2013.
Bernards N; Haj Mohammad N; Creemers GJ; Rozema T; Roukema JA; Nieuwenhuijzen GA; van Laarhoven HW; van der Sangen M; Lemmens VE
Acta Oncol; 2016; 55(9-10):1161-1167. PubMed ID: 27174793
[TBL] [Abstract][Full Text] [Related]
31. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
[TBL] [Abstract][Full Text] [Related]
32. Multidisciplinary approach to esophageal and gastric cancer.
Stein HJ; Sendler A; Fink U; Siewert JR
Surg Clin North Am; 2000 Apr; 80(2):659-82; discussions 683-6. PubMed ID: 10836011
[TBL] [Abstract][Full Text] [Related]
33. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.
Schmidt T; Alldinger I; Blank S; Klose J; Springfeld C; Dreikhausen L; Weichert W; Grenacher L; Bruckner T; Lordick F; Ulrich A; Büchler MW; Ott K
Eur J Surg Oncol; 2015 Oct; 41(10):1340-7. PubMed ID: 26213358
[TBL] [Abstract][Full Text] [Related]
34. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy.
Mizrak Kaya D; Wang X; Harada K; Blum Murphy MA; Das P; Minsky BD; Estrella JS; Lin Q; Amlashi FG; Lee JH; Weston B; Bhutani MS; Matamoros A; Sagebiel T; Wu CC; Rogers JE; Thomas I; Maru DM; Skinner HD; Badgwell BD; Hofstetter WL; Ajani JA
Oncology; 2017; 93(4):243-248. PubMed ID: 28683449
[TBL] [Abstract][Full Text] [Related]
35. Survival and cardiac toxicity in patients with HER2-positive, metastatic breast cancer treated with trastuzumab in routine clinical practice.
Vasista A; Ryan L; Naher S; Moylan E; Stockler MR; Wilcken N; Kiely BE
Asia Pac J Clin Oncol; 2020 Feb; 16(1):34-38. PubMed ID: 31657878
[TBL] [Abstract][Full Text] [Related]
36. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
[TBL] [Abstract][Full Text] [Related]
37. Treatment strategies in recurrent esophageal or junctional cancer.
Butter R; Lagarde SM; van Oijen MGH; Anderegg MCJ; Gisbertz SS; Meijer SL; Hulshof MCCM; Bergman JJGHM; van Berge Henegouwen MI; van Laarhoven HWM
Dis Esophagus; 2017 Sep; 30(9):1-9. PubMed ID: 28859371
[TBL] [Abstract][Full Text] [Related]
38. Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer.
Hingorani M; Dixit S; Johnson M; Plested V; Alty K; Colley P; Beavis AW; Roy R; Maraveyas A
Cancer Res Treat; 2015 Oct; 47(4):706-17. PubMed ID: 25687854
[TBL] [Abstract][Full Text] [Related]
39. Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
Dijksterhuis WPM; Verhoeven RHA; Pape M; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2020 Nov; 139():107-118. PubMed ID: 32980749
[TBL] [Abstract][Full Text] [Related]
40. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
